Forcing dividing cancer cells to die; low-dose drug combinations to prevent spindle pole clustering

被引:4
|
作者
Ducrey, Eloise [1 ,2 ,3 ]
Castrogiovanni, Cedric [3 ,4 ]
Meraldi, Patrick [3 ,4 ]
Nowak-Sliwinska, Patrycja [1 ,2 ,3 ]
机构
[1] Univ Geneva, Sch Pharmaceut Sci, Fac Sci, CMU, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland
[2] Univ Geneva, Inst Pharmaceut Sci Western Switzerland, CMU, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland
[3] Translat Res Ctr Oncohaematol, CMU, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland
[4] Univ Geneva, Dept Cell Physiol & Metab, Sch Med, CMU, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland
基金
瑞士国家科学基金会;
关键词
Mitosis; Drug combination; Cancer; Centrosome clustering;
D O I
10.1007/s10495-021-01671-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mitosis, under the control of the microtubule-based mitotic spindle, is an attractive target for anti-cancer treatments, as cancer cells undergo frequent and uncontrolled cell divisions. Microtubule targeting agents that disrupt mitosis or single molecule inhibitors of mitotic kinases or microtubule motors kill cancer cells with a high efficacy. These treatments have, nevertheless, severe disadvantages: they also target frequently dividing healthy tissues, such as the haematopoietic system, and they often lose their efficacy due to primary or acquired resistance mechanisms. An alternative target that has emerged in dividing cancer cells is their ability to "cluster" the poles of the mitotic spindle into a bipolar configuration. This mechanism is necessary for the specific survival of cancer cells that tend to form multipolar spindles due to the frequent presence of abnormal centrosome numbers or other spindle defects. Here we discuss the recent development of combinatorial treatments targeting spindle pole clustering that specifically target cancer cells bearing aberrant centrosome numbers and that have the potential to avoid resistance mechanism due their combinatorial nature.
引用
收藏
页码:248 / 252
页数:5
相关论文
共 50 条
  • [1] Forcing dividing cancer cells to die; low‐dose drug combinations to prevent spindle pole clustering
    Eloise Ducrey
    Cédric Castrogiovanni
    Patrick Meraldi
    Patrycja Nowak-Sliwinska
    Apoptosis, 2021, 26 : 248 - 252
  • [2] Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering
    Weiss, Andrea
    Le Roux-Bourdieu, Morgan
    Zoetemelk, Marloes
    Ramzy, George M.
    Rausch, Magdalena
    Harry, Daniela
    Miljkovic-Licina, Marijana
    Falamaki, Katayoun
    Wehrle-Haller, Bernard
    Meraldi, Patrick
    Nowak-Sliwinska, Patrycja
    CANCERS, 2019, 11 (10)
  • [3] Phosphoproteomics guides effective low-dose drug combinations against pancreatic ductal adenocarcinoma
    Valles-Marti, Andrea
    Mantini, Giulia
    Manoukian, Paul
    Waasdorp, Cynthia
    Sarasqueta, Arantza Farina
    de Goeij-de Haas, Richard R.
    Henneman, Alex A.
    Piersma, Sander R.
    Pham, Thang V.
    Knol, Jaco C.
    Giovannetti, Elisa
    Bijlsma, Maarten F.
    Jimenez, Connie R.
    CELL REPORTS, 2023, 42 (06):
  • [4] Synergistic Growth Inhibition of PC3 Prostate Cancer Cells with Low-dose Combinations of Simvastatin and Alendronate
    Rogers, Mailien
    Kalra, Sumit
    Moukharskaya, Julia
    Chakraborty, Kanishka
    Niyazi, Maximilian
    Krishnan, Koyamangalath
    Lightner, Janet
    Brannon, Marianne
    Stone, William L.
    Palau, Victoria E.
    ANTICANCER RESEARCH, 2015, 35 (04) : 1851 - 1859
  • [5] LOW-DOSE ASPIRIN USE TO PREVENT COLORECTAL CANCER AND CARDIOVASCULAR DISEASE: AN UPDATE
    Morrow, Linda
    Greenwald, Beverly
    GASTROENTEROLOGY NURSING, 2023, 46 (01) : 76 - 77
  • [6] Low-dose curcuminoid-loaded in dextran nanobubbles can prevent metastatic spreading in prostate cancer cells
    Bessone, F.
    Argenziano, M.
    Grillo, G.
    Ferrara, B.
    Pizzimenti, S.
    Barrera, G.
    Cravotto, G.
    Guiot, C.
    Stura, I
    Cavalli, R.
    Dianzani, C.
    NANOTECHNOLOGY, 2019, 30 (21)
  • [7] AtFH8 Is Involved in Root Development under Effect of Low-Dose Latrunculin B in Dividing Cells
    Xue, Xiu-Hua
    Guo, Chun-Qing
    Du, Fei
    Lu, Quan-Long
    Zhang, Chuan-Mao
    Ren, Hai-Yun
    MOLECULAR PLANT, 2011, 4 (02) : 264 - 278
  • [8] Challenging an Old Drug in a New Context: Low-Dose Cyclophosphamide in Immunogenetherapy of Cancer
    Tuve, Sebastian
    Ni, Shaoheng
    Lieber, Andre
    MOLECULAR THERAPY, 2006, 13 : S236 - S237
  • [9] Low-dose sequential multi-drug regimens for advanced pancreatic cancer
    Bruckner, H.
    Simon, K.
    Hrehorovich, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)